LeMaitre Vascular (LMAT) to Release Quarterly Earnings on Tuesday

Key Points

• LeMaitre Vascular is set to release its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.57 per share and revenue of $62.48 million.
• In its last earnings report, LeMaitre Vascular had earnings of $0.48 per share, falling short of the $0.50 consensus estimate, although revenue rose by 12% year-over-year.
• Insider trading reports indicate that CEO George W. Lemaitre sold 4,399 shares in May, with total insider sales amounting to approximately $8.56 million over the last three months.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect LeMaitre Vascular to post earnings of $0.57 per share and revenue of $62.48 million for the quarter. LeMaitre Vascular has set its Q2 2025 guidance at 0.550-0.590 EPS and its FY 2025 guidance at 2.070-2.240 EPS.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The firm's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.44 earnings per share. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded down $0.47 on Wednesday, hitting $81.97. 86,456 shares of the stock traded hands, compared to its average volume of 101,348. The firm has a 50 day simple moving average of $82.48 and a two-hundred day simple moving average of $87.18. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 2.17 and a beta of 0.82. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total value of $374,354.90. Following the sale, the chief executive officer owned 1,827,003 shares of the company's stock, valued at $155,477,955.30. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 100,000 shares of company stock valued at $8,556,857. Insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

A number of large investors have recently added to or reduced their stakes in LMAT. Strs Ohio purchased a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $168,000. Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares during the period. Intech Investment Management LLC boosted its holdings in shares of LeMaitre Vascular by 116.6% in the 1st quarter. Intech Investment Management LLC now owns 20,967 shares of the medical instruments supplier's stock worth $1,759,000 after purchasing an additional 11,288 shares during the period. Jane Street Group LLC boosted its holdings in shares of LeMaitre Vascular by 738.7% in the 1st quarter. Jane Street Group LLC now owns 20,096 shares of the medical instruments supplier's stock worth $1,686,000 after purchasing an additional 17,700 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of LeMaitre Vascular by 5.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 37,709 shares of the medical instruments supplier's stock worth $3,164,000 after purchasing an additional 1,972 shares during the period. Institutional investors own 84.64% of the company's stock.

Analysts Set New Price Targets

Separately, Barrington Research reissued a "market perform" rating on shares of LeMaitre Vascular in a research note on Tuesday, July 22nd. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of "Hold" and an average target price of $97.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.